Regd. Office :-

330, TRIVIA Complex, Natubhai Circle, Racecourse, Vadodara – 390007, Gujarat, INDIA

Phone : +91 265 2988903 / 2984803 Website : www.chemcrux.com Email : girishshah@chemcrux.com





To

06th November 2025

BSE LIMITED

Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001

Dear Sir/Madam

Subject: Unaudited Financial Results for the quarter and half year ended 30th September 2025

Ref: BSE Scrip ID: CHEMCRUX **BSE Scrip Code**: 540395

We would like to inform that the Board of Directors in its meeting held today i.e., 06th November 2025 inter alia, considered and approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2025 as recommended by the Audit Committee.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2025.

Kindly take above as compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 11.30 A.M. and concluded at 01:45 P.M.

Thanking you

For CHEMCRUX ENTERPRISES LIMITED

Dipika Rajpal

Company Secretary & Compliance Officer

naresh & co.

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

To,
The Board of Directors,
Chemcrux Enterprises Limited,

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Chemcrux Enterprises Limited ('the Company") for the quarter and six months ended 30th September 2025 ('the Statement') attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")

This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, together with the Notes thereon and read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Naresh & Co.

Chartered Accountants

FRN: 106928W

CA Harin Parikh

Partner

M.No. 107606

UDIN: 25107606BMOJIC9201

Place: Vadodara

CHEMCRUX ENTERPRISES LIMITED CIN: L01110GJ1996PLC029329

Reg. Office: 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007
UNAUDITED STANDALONE BALANCE SHEET AS AT 30th SEPTEMBER, 2025

(All amounts are in INR Lacs, Unless otherwise stated)

	Particulars	30-09-2025	31-03-2025
	Particulars	Unaudited	Audited
1.	ASSETS		
(1)	Non - current assets	5 505 50	5 530 00
- 1	(a) Property, Plant and Equipment	5,595.50	5,639.86
- 1	(b) Capital Work In Progress	391.97	161.08
- 1	(c) Investment Property	67.78	67.78
- 1	(d) Right of use assets	38.06	44.23
- 1	(e) Intangible assets	2.84	2.84
- 1	(f) Financial assets		-
- 1	(i) Investments	5.70	5.70
- 1	(ii) Loans	696.25	559.00
	(iil) Others	308.70	275.47
	(g) Other non - current assets		-
(2)	Current assets		
	(a) Inventories	466.96	964.89
- 1	(b) Financial assets	-	
	(i) Investments	1,644.92	1,978.15
- 1	(ii) Trade receivables	1,515.88	1,221.30
	(iii) Cash and cash equivalents	153.53	101.38
- 1	(iv) Bank balances other than cash and cash equivalents	149.07	12.88
	(v) Loans	26.23	23.48
- 1	(vi) Others	3.64	6.21
	(c) Other current assets	205.05	150.28
		44.000.00	11.511.51
II. E	Total Assets EQUITY AND LIABILITIES	11,272.07	11,214.51
11.	EQUIT AND EIABILITIES		
(1) <u>E</u>	Equity		
	(a) Equity Share capital	1,480.88	1,480.88
	(b) Other equity	6,251.87	6,130.30
1	Liabilities		
-	Non - current liabilities		
,-/ -	(a) Financial liabilities		
	(i) Long Term Borrowings	1,556.24	1,787.74
	(ii) Lease Liabilities	51.28	60.70
	(iii) Other Financial Liabilities		
	(b) Provisions	24.20	5.57
	(c) Deferred Tax Liability (net)	364.11	346.46
	2		
(3)	Current liabilities		
	(a) Financial liabilities	24242	046.0
	(i) Short Term Borrowings	747.17	816.02
	(ii) Lease Liabilities	18.30	16.54
	(iii) Trade payables a)Total outstanding dues of micro enterprises		
- 1	and small enterprises	101.55	26.44
	b)Total outstanding dues of creditors others than micro	202133	2011
- 1	enterprises and small enterprises	463.24	374.66
	(iv) Other financial liabilities	55.26	60.42
- 1	(c) Other current liabilities	157.98	108.77
	(b) Provisions	137.30	108.77
			-
			1921
	(d) Current tax liabilities (net)	*	*



CHEMCRUX ENTERPRISES LIMITED

CIN: L01110GJ1996PLC029329

Reg. Office: 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007
UNAUDITED STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER 2025

(All amounts are in INR lacs, unless otherwise stated)

	Particulars	Quarter Ended			Half Year Ended		Year ended	
	Fatherials	30-09-2025 Unaudited	30-06-2025 Unaudited	30-09-2024 Unaudited	30-09-2025 Unaudited	30-09-2024 Unaudited	31-03-202 Audited	
1.	Revenue from operations	1,855.31	1,674.74	1,775.62	3,530.04	3,486.47	7,025.39	
11.	Other income	79.81	60.70	25.90	140.52	64.67	152.96	
III.	Total Income (I+II)	1,935.12	1,735.44	1,801.52	3,670.56	3,551.15	7,178.3	
IV.	Expenses:					~		
	Cost of materials consumed Purchase of Traded Goods	757.66	552.72	741.46	1,310.38	1,439.43	3,042.2	
	Changes in inventories of finished goods, by-products and work in progress	188.58	325.80	(36.95)	514.38	11.48	(236.20	
	Employee benefits expense	211.23	201.99	211.27	413.23	416.61	852.68	
	Finance costs	52.02	52.41	32.79	104.44	45.95	163.8	
	Depreciation and amortization expense	96.26	94.66	73.47	190.92	129.50	313.00	
	Other expenses	531.10	434.79	623.88	965.89	1,176.46	2,460.0	
	Total expenses (IV)	1,836.85	1,662.38	1,645.91	3,499.24	3,219.43	6,595.54	
٧.	Profit Before Tax	98.27	73.06	155.61	171.32	331.72	582.83	
VIII.	Tax expense :			- 3		-		
	Current tax	8.20	1.42	100	9.62	45.30	75.00	
	Deferred tax Income tax relating to earlier years	10.12	13.19	40.86	23.31	47.85	90.0	
	income tax relating to earner years	18.32	14.61	40.86	32.93	93.15	163.9	
IX.	Profit for the period	79.95	58.45	114.75	138.39	238.57	418.86	
		73.33	30.43	114.75	130.33	230.37	410.00	
X	Other comprehensive income							
	Items that will not be reclassified to profit or loss Defined Benefit Plan	(0.58)	(13.06)	(9.33)	(13.64)	3.83	26.18	
	(ii) Income tax relating to items that will not be	(0.15)	(3.29)	(2.35)	(3.43)	0.96	6.59	
	reclassified to profit or loss	,,	1-1-2	(=:==1	(/			
	(iii) Items that will be reclassified to profit or loss							
	-Fair Value Gain on Investments	26.56	40.21	39.24	66.77	75.17	126.92	
	(iv) Income tax relating to items that will be reclassified to profit or loss	6.68	10.12	9.88	16.81	18.92	31.95	
	Total other comprehensive income, net of tax	19.44	20.32	22.38	39.76	59.11	114.57	
XI.	Total comprehensive income for the period	99.39	78.76	137.13	178.15	297.68	533.42	
XII.	Earnings per equity share (Nominal value per share Rs. 10/-)			6				
	- Basic (Rs.)	0.54	0.39	0.77	0.93	1.61	2.83	
	- Diluted (Rs.)	0.54	0.39	0.77	0.93	1.61	2.83	



Notes to Standalone Financial Results :

- The above financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- The above financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 06th Novemebr, 2025.
- 3 The Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of ind AS 108, an Operating Segment, constitute a single operating segment.
- 4 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

For & on behalf of the Board Chemorux Enterprises Limited

Girishkumar Shah Whole Time Director DIN: 00469291

Place : Vadodara

CHEMCRUX ENTERPRISES LIMITED CIN: L01110GJ1996PLC029329

Reg. Office: 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007 UNAUDITED STANDALONE STATEMENT OF CASH FLOW FOR THE PERIOD ENDED 30TH SEPTEMBER, 2025

(All amounts are in INR Lacs, Unless otherwise stated)

Sr.	ltem	Half Year ended 30th September , 2025	Half Year ended 30th September, 2024	
A.	Cash flow from Operating Activities :			
	Net Profit before Tax & Extra Ordinary Items	171.32	331.72	
	Adjustment for :			
	Depreciation & Write-offs	190.92	129.50	
	Loss/(Profit) on Sale of Investments/Assets	(75.61)	(5.98	
	Employee Benefit	6.98	6.80	
	Interest Paid	102.85	41.8	
	Operating Profit before Working Capital Changes	396.46	503.9	
	Adjustments for :			
	(Increase)/Decrease in Trade Receivables	(294.58)	(169.8	
	(Increase)/Decrease in Inventories	497.93	88.5	
	(Increase)/Decrease in Loans & Advances	(170.67)	(145.4	
	(Increase)/Decrease in other current assets	1.47	(70.2	
	Increase/(Decrease) in Trade Payable	163.68	134.6	
	Increase/(Decrease) in Other Current Liabilities	28.05	93.5	
	Increase/(Decrease) in Long term provisions	(2.00)	170	
	Cash Generated from Operations	620.35	435.0	
	Direct Taxes Paid (Net of Refund)	(65.86)	(75.8	
	Cash Flow before Extra Ordinary Items	554.49	359.2	
	Net Cash Flow from Operating Activities	554.49	359.2	
В.	Cash flow from Investing Activities			
	Purchase of Fixed Assets	(371.28)	(581.3	
	Net Proceeds from Sale of Property Plant & Equipment		17.0	
	Investments	400.00	-	
	Net Cash used in Investment Activities	28.72	(564.3	
C.	Cash Flow from Financing Activities			
	Interest Paid	(83.89)	(41.8	
	Increase/(Decrease) in Short Term Borrowings	(68.84)	392.6	
	Increase/(Decrease) in Lease Liabilities	(10.62948)	(6.1	
	Increase/(Decrease) in Long Term Borrowings	(231.50)	(160.6	
	Dividend Paid	-	(148.0	
	Net Cash used in Financing Activities	(394.87)	35.8	
D.	Net Increase/(Decrease) in Cash and Cash Equivalents	188.34	(169.2	
	Cash and Cash Equivalents at beginning of period	114.26	518.2	
	Cash and Cash Equivalents at the end of the period	302.60	349.0	
		,		



INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON CONSOLIDATED FINANCIAL RESULTS

To,
The Board of Directors,
Chemcrux Enterprises Limited,

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Chemcrux Enterprises Limited ('the Holding Company") and its Subsidiary ("Kalichem Private Limited") (the Holding Company and its Subsidiary together referred to as "the Group") for the quarter and six months ended 30th September 2025, read together with the Notes thereon ('the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") as amended.

This Statement, which is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable

The Statement includes the results of M/s. Kalichem Private Limited (Subsidiary)

Based on our review conducted and procedures performed as stated above, including the limited review of the unaudited financial results of the subsidiary company performed by us, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

CHARTERED ACCOUNT

Other Matters

a) The Holding Company initially held 50% stake in Kalichem Private Limited making it a Joint Venture. The Holding Company acquired balance 50% stake in Kalichem Private Limited from the co-venturer M/s. Kalintis Healhcare Private Limited on 27th February, 2025. As a result of the acquisition, Kalichem Private Limited became a wholly-owned subsidiary of the Holding Company from that date.

Consequently, the Company has Consolidated the Financial Results of Kalichem Private Limited as a Joint Venture under the Equity Method in accordance with Ind AS 28 till 27th February, 2025 i.e. the date on which Kalichem Private Limited became a wholly-owned subsidiary. For the subsequent period, i.e. from 27th February, 2025 to 31st March, 2025, the Consolidation has been done as a Wholly Owned Subsidiary under Ind AS 110 following the principles of Ind AS 103 Business Combinations.

The consolidated figures relating to the various periods appearing in the Statement are in accordance with the above.

b) The Statement includes the figures relating to quarter and six month ended 30th September, 2024 for which the financial results of M/s. Kalichem Private Limited were reviewed by other auditors whose review reports have been furnished to us. At that time M/s. Kalichem Private Limited was a Joint Venture and Consolidated under the Equity Method. Our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of Kalichem Private Limited for the quarter and six months ended 30th September, 2024 is based solely on the report of the other auditor and the procedures performed by us as stated above.

Our Conclusion on the Statement is not modified in respect of the above Other Matters.

For Naresh & Co

Chartered Accountants

FRN: 106928W

EA Harin Parikh

Partner

M.No. 107606

UDIN: 25107606BMOJID9722

Place: Vadodara

CHEMCRUX ENTERPRISES LIMITED CIN: L01110GJ1996PLC029329

Reg. Office: 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007 UNAUDITED CONSOLIDATED BALANCE SHEET AS AT 30th SEPTEMBER, 2025
(All amounts are in INR Lacs, Unless otherwise stated)

	Particulars	30-09-2025	31-03-2025
	Particulars	Unaudited	Audited
I. ASS	SETS		
(2)			
	n - current assets	7.500.45	
2.0	Property, Plant and Equipment	7,506.16	7,580.
	Capital Work In Progress	391.97	161.
) Investment Property	67.78	67.
) Right of use assets	38.06	44.
) Intangible assets	12.84	12.
(1)) Financial assets	9733307	
	(i) Investments	4.70	4.
	(ii) Loans		
	(iil) Others	202.27	200.
(g)) Other non - current assets	-	
(2) Cur	rrent assets		
(a)) Inventories	518.99	1,001.
(b)) Financial assets		,
1 35	(i) Investments	1,644.92	1,978.
	(ii) Trade receivables	1,348.69	1,178
- 1	(iii) Cash and cash equivalents	154.27	101.
	(iv) Bank balances other than cash and cash equivalents	149.07	12.
- 1	(v) Loans	26.23	23.
- 1	(vi) Others	4.12	7.
(c)	Other current assets	375.66	329
I. EQL	Total Assets UITY AND LIABILITIES	12,445.72	12,704.
II. ILQU	off AND CABICITES	*	
(1) <u>Equ</u>	uity		
(a)) Equity Share capital	1,480.88	1,480.
(b)) Other equity	5,995.10	5,981.
Link	bilities		
	n - current liabilities		
	Financial liabilities		
(a)	(i) Long Term Borrowings	2,491.28	2,804.
	(ii) Lease Liabilities	51.28	60.
	(iii) Other Financial Liabilities	51.26	00.
(h)	Provisions	24.20	5.
	Deferred Tax Liability (net)	364.11	367.
2000		1000	
Sc (5) 10	rent liabilities		
(a)	Financial liabilities		
	(i) Short Term Borrowings	1,179.30	1,348.
	(ii) Lease Liabilities	18.30	16.
	(iii) Trade payables a)Total outstanding dues of micro enterprises		
	and small enterprises	132.61	45.
- 1	b)Total outstanding dues of creditors others than micro		
- 1	enterprises and small enterprises	472.92	403.
	(iv) Other financial liabilities	68.91	72.
(c)	Other current liabilities	166.83	118.
(b)	Provisions		
(d)	Current tax liabilities (net)		1 1 1
-	**************************************		
	Total Equity and Liabilities	12,445.72	12,704.



CHEMCRUX ENTERPRISES LIMITED

CIN: L01110GJ1996PLC029329

Reg. Office: 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER 2025

(All amounts are in INR Lacs, unless otherwise stated)

	I		Ouasta F.J.				nerwise stated)
	Particulars	Quarter Ended			Half Year Ended		Year ended
		30-09-2025 Unaudited	30-06-2025 Unaudited	30-09-2024 Unaudited	30-09-2025 Unaudited	30-09-2024 Unaudited	31-03-2025 Audited
l.	Revenue from operations	1,774.63	1,650.35	1,775.62	3,424.98	3,486.47	7,000.99
II.	Other income	62.50	44.07	25.90	106.57	64.67	148.74
III.	Total Income (I+II)	1,837.13	1,694.43	1,801.52	3,531.55	3,551.15	7,149.73
IV.	Expenses:						
	Cost of materials consumed Purchase of Traded Goods	623.03	472.02	741.46	1,095.05	1,439.43	2,978.53
	Changes in inventories of finished goods, by-products and work in progress	156.20	325.80	(36.95)	482.00	11.48	(236.26
	Employee benefits expense	225.10	213.11	211.27	438.21	416.61	856.44
	Finance costs	82.60	85.81	32.79	168.41	45,95	174.55
	Depreciation and amortization expense	119.57	117.69	73.47	237.27	129.50	320.56
	Other expenses	591.01	476.90	623.88	1,067.91	1,176.46	2,479.38
٧.	Total expenses (IV)	1,797.52	1,691.33	1,645.91	3,488.85	3,219.43	6,573.19
VI.	Profit Before Share in profit of Joint Venture (III-IV)	39.61	3.09	155.61	42.70	331.72	576.54
VII.	Share in Profit/(Loss) of Joint Venture (Net of Tax)	3.6			~	· ·	(0.50)
VIII.	Profit Before Tax	39.61	3.09	155.61	42.70	331.72	576.04
IX.	Tax expense :						
	Current tax	8.20	1.42		9.62	45.30	75.00
	Deferred tax	10.12	(7.59)	40.86	2.53	47.85	110.85
	Income tax relating to earlier years	111000000000000000000000000000000000000			-		(1.11)
		18.32	(6.17)	40.86	12.15	93.15	184.74
х.	Profit for the period	21.29	9.27	114.75	30.55	238.57	391.30
XI.	Other comprehensive income (i) Items that will not be reclassified to profit or loss - Defined Benefit Plan (ii) Income tax relating to items that will not be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss - Fair Value Gain on Investments (iv) Income tax relating to items that will be reclassified to profit or loss	(0.58) (0.15) 26.56 6.68	(13.05) (3.29) 40.21 10.12	(9.33) (2.35) 39.24 9.88	(13.64) (3.43) 66.77 16.81	3.83 0.96 75.17 18.92	26.18 6.59 126.92 31.95
	Total other comprehensive income, net of tax	19.44	20.32	22.38	39.76	59.11	114.57
XII.	Total comprehensive income for the period	40.73	29.58	137.13	70.31	297.68	505.87
	Profit for the period/year attributable to: Owners of the Company	21.29	9.27		30.55		391.30
	Other comprehensive income for the period/year attributable to:				9 90		
	Owners of the Company	19.44	20.32		39.76	-	114.57
	Total comprehensive income for the period attributable to: Owners of the Company	40.73	29.58		70.31		505.87
XIII.	Earnings per equity share (Nominal value per share Rs. 10/-) - Basic (Rs.)	0.14	0.06	0.77	0.21	1.61	2.64
	- Diluted (Rs.)	0.14	0.06	0.77	0.21	1.61	2.64



Notes to Consolidated Financial Results:

1 List of Entities Consolidated included in the

Kalichem Private Limited
Joint Venture till 26.02.2025
Wholly-Owned Subsidiary from 27.02.2025

- 2 The above consolidated financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 3 The above consolidated financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 06th November, 2025
- 4 The Holding Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of in AS 108, on Operating Segment, constitute a single operating segment.
- 5 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

For & on behalf of the Board Chemcrux Enterprises Limited

Girishkumar Shah Whole Time Director DIN: 00469291

Place : Vadodara

CHEMCRUX ENTERPRISES LIMITED CIN: L01110GJ1996PLC029329

Reg. Office: 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007 UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE PERIOD ENDED 30TH SEPTEMBER, 2025

(All amounts are in INR Lacs, Unless otherwise stated)

Sr.	Item	Half Year ended 30th September , 2025	Half Year ended 30th September 2024
Α.	Cash flow from Operating Activities :		
	Net Profit before Tax & Extra Ordinary Items	42.70	331.72
	Adjustment for :		
	Depreciation & Write-offs	237.27	129.50
	Loss/(Profit) on Sale of Investments	(75.61)	(5.98
	Interest Paid	163.36	41.87
	Operating Profit before Working Capital Changes	367.71	497.11
	Adjustments for :		
	(Increase)/Decrease in Trade Receivables	(170.61)	(169.85
	(Increase)/Decrease in Inventories	482.67	88.51
	(Increase)/Decrease in Loans & Advances	(1.25)	(145.41
	(Increase)/Decrease in other current assets	(5.14)	(70.29
	Increase/(Decrease) in Trade Payable	156.98	134.60
	Increase/(Decrease) in Other Current Liabilities	44.69	93.56
	Increase/(Decrease) in Long term provisions	(2.00)	6.80
	Cash Generated from Operations	873.05	435.03
	Direct Taxes Paid (Net of Refund)	(66.07)	(75.80
	Cash Flow before Extra Ordinary Items	806.97	359.23
	Prior Period Items (being cash items)		
	Net Cash Flow from Operating Activities	806.97	359.23
В.	Cash flow from Investing Activities		
	Purchase of Fixed Assets	(387.21)	(581.36
	Net Proceeds from Sale of Property Plant & Equipment	-	17.00
	Dividend Received		
	Investments	400.00	
	Net Cash used in Investment Activities	12.79	(564.36
C.	Cash Flow from Financing Activities	100	
	Interest Paid	(138.09)	(41.87
	(Increase)/Decrease in Other Non current Assets		*
	Increase/(Decrease) in Short Term Borrowings	(168.71)	392.60
	Increase/(Decrease) in Lease Liabilities	(10.63)	(6.14
	Increase/(Decrease) in Long Term Borrowings	(313.51)	(160.61
	Dividend Paid	-	(148.09
	Net Cash used in Financing Activities	(630.94)	35.89
D.	Net Increase/(Decrease) in Cash and Cash Equivalents	188.83	(169.23
	Cash and Cash Equivalents at beginning of period	114.52	518.24
	Cash and Cash Equivalents at the end of the period	303.35	349.01

